UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 20, 2014
ARROGENE, INC.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation or organization) | 000-53018 Commission File Number | 20-8057585 (I.R.S. Employer Identification Number) |
2500 Broadway, Bldg. F, Suite F-125
Santa Monica, CA 90404
(Address of principal executive offices)
(424) 238-4442
(Issuer’s Telephone Number)
___________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 | OTHER EVENTS |
Arrogene, Inc., a Delaware corporation (the “Company”) has prepared a letter to its shareholders updating recent developments in the form attached hereto as exhibit 99.1.
ITEM 9.01: EXHIBITS
| (c) | Exhibit |
|
|
|
| Item | Title |
|
|
|
| 99.1 | Letter to shareholders dated February 20, 2014. |